For countless seniors, accessing affordable medication has been a lifeline, with many turning to Canadian pharmacies for significant savings. But here's where it gets controversial: recent policy shifts threaten to cut off this vital resource, leaving vulnerable populations in a precarious position. Take Linda Klonsky, for instance, a 75-year-old who relies on prescription eye drops. She’s been paying just $250 for a three-month supply from a Canadian pharmacy—a price that’s nearly nine times lower than what she’d pay domestically. Yet, this summer, her routine refill hit an unexpected roadblock. The Trump administration’s trade policies prompted international postal services to halt shipments to the U.S., forcing Linda to turn to her local CVS in Silver Spring, Maryland. There, she shelled out $740 for a mere 30-day supply of the same medication. And this is the part most people miss: it’s not just about higher costs—it’s about accessibility and the broader implications for healthcare affordability. While some argue these policies protect domestic industries, others question whether they unfairly penalize those who rely on international options. What do you think? Is this a necessary trade-off, or does it unfairly burden those who need affordable medication the most? Share your thoughts in the comments—this is a conversation that deserves to be heard.
